Contact Us
Drug Search Results
More Filters [+]

Vadadustat

Alternative Names: vadadustat, akb-6548, akb6548, akb 6548
Latest Update: 2024-12-18
Latest Update Note: News Article

Product Description

Vadadustat is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, a class of drugs that stabilize HIF and stimulate erythropoietin and red-cell production. (Sourced from: https://www.nejm.org/doi/full/10.1056/NEJMoa2035938)

Mechanisms of Action: HIF Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Belgium | Croatia | European Medicines Agency | Finland | Iceland | Japan | Korea | Lithuania | Poland | Portugal | Slovakia | Sweden

Approved Indications: None

Known Adverse Events: None

Company: Akebia
Company Location: CAMBRIDGE MA 02142
Company CEO: John P. Butler
Additonal Commercial Interests: Otsuka

Clinical Description

Map of Global Clinical Trials for Vadadustat

Countries in Clinic: United States

Active Clinical Trial Count: 8

Highest Development Phases

Phase 3: Anemia|Kidney Diseases|Kidney Failure, Chronic

Phase 2: Acute Lung Injury|Acute Respiratory Distress Syndrome|COVID-19|Respiratory Distress Syndrome, Newborn

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2021-003994-72

P3

Temporarily not available

Kidney Diseases|Anemia

2027-01-27

2021-004022-30

P3

Temporarily not available

Anemia|Kidney Diseases

2027-01-25

CORRECTION

P3

Suspended

Anemia|Kidney Failure, Chronic

2026-07-01

39%
CONVERSION

P3

Suspended

Anemia|Kidney Failure, Chronic

2026-07-01

39%

Recent News Events

Date

Type

Title

12/18/2024

News Article

 Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

12/03/2024

News Article

 U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis

11/14/2024

News Article

 Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

10/22/2024

News Article

 Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions